An official says this is the first drug that addresses the underlying biology of the disease.
The Food and Drug Administration (FDA) has approved Orzeyful (oveporexton), a drug used to treat narcolepsy type 1 in adults. The drug is the first of its kind to address the full range of symptoms caused by the disease. One in 2,000 individuals in the U.S. is affected by narcolepsy. Symptoms can range from excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations.
The FDA explained, “Rather than masking symptoms with stimulants or sedatives, Orzeyful directly activates the same brain receptor that the body’s own orexin would normally stimulate, restoring the missing signal.”
“For too long, people with narcolepsy type 1 have had to manage a complex, lifelong neuropsychiatric with treatments that only address pieces of it,” said Director Tiffany Farchione of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research. “This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsytype 1 as a whole.”
As the Lord Leads, Pray with Us…
- For Acting Commissioner Diamantas as he oversees the FDA approvals of drugs and medications.
- For Secretary Kennedy as he heads the Department of Health and Human Services.
- For those affected by narcolepsy who may be helped by the new medication.
Sources: U.S. Food and Drug Administration, UPI News
